2022年 新着論文 13 免疫制御学分野、発生生物学分野から論文が発表されました

PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

Nat Immunol. 2022 Mar;23(3):399-410. doi: 10.1038/s41590-021-01125-7. Epub 2022 Feb 10.

Authors

Daisuke Sugiura  1   2 Il-Mi Okazaki  1   2 Takeo K Maeda  2 Takumi Maruhashi  1   2 Kenji Shimizu  1   2 Rieko Arakaki  3 Tatsuya Takemoto  4 Naozumi Ishimaru  3 Taku Okazaki  5   6

Affiliations

  • 1 Laboratory of Molecular Immunology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
  • 2 Laboratory for Immune Regulation, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
  • 3 Department of Oral Molecular Pathology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • 4 Laboratory for Embryology, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
  • 5 Laboratory of Molecular Immunology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan. tokazaki@iqb.u-tokyo.ac.jp.
  • 6 Laboratory for Immune Regulation, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan. tokazaki@iqb.u-tokyo.ac.jp.

Abstract

Targeted blockade of the checkpoint molecule programmed cell death 1 (PD-1) can activate tumor-specific T cells to destroy tumors, whereas targeted potentiation of PD-1 is expected to suppress autoreactive T cells and alleviate autoimmune diseases. However, the development of methods to potentiate PD-1 remains challenging. Here we succeeded in eliciting PD-1 function by targeting the cis-PD-L1-CD80 duplex, formed by binding of CD80 to the PD-1 ligand PD-L1, that attenuates PD-L1-PD-1 binding and abrogates PD-1 function. By generating anti-CD80 antibodies that detach CD80 from the cis-PD-L1-CD80 duplex and enable PD-L1 to engage PD-1 in the presence of CD80, we demonstrate that the targeted dissociation of cis-PD-L1-CD80 duplex elicits PD-1 function in the condition where PD-1 function is otherwise restricted. We demonstrate using murine models that the removal of PD-1 restriction is effective in alleviating autoimmune disease symptoms. Our findings establish a method to potentiate PD-1 function and propose the removal of restraining mechanisms as an efficient strategy to potentiate the function of inhibitory molecules.

Comment in

Full text links

Nature Publishing Group